64 completed, 19 unknown, 18 terminated, 14 active not recruiting. 143 Phase 2, 18 Phase 3, 15 Phase 1.
Follow Gallbladder Diseases: new trials by email Literature Review of Gallbladder Diseases trials Research Report on Gallbladder Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-11-10 |
| A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic Cholecystectomy Anrikefon, Dezocine - Gallbladder Stones, Gallbladder Polyps | Phase 2 | Not yet recruiting | Affiliated Hospital of Guangdong Medical University | 144 | 2026-09-01 | 2026-08-03 |
| AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer AK112, Gemcitabine, Cisplatin - Gallbladder Cancer | Phase 2 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 22 | 2026-08-28 | 2026-08-17 |
| Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study Postoperative radiotherapy, Capecitabine or S-1 - Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 92 | 2026-06-16 | 2026-06-24 |
| A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. GV20-0251, anti-PD-1 monoclonal antibodies - Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms | Phase 2 | Not yet recruiting | GV20 Therapeutics | 227 | 2026-06-02 | 2026-06-08 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib - Biliary Tract Neoplasms, Advanced Cancer | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 160 | 2025-12-01 | 2025-12-08 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer Comprehensive Geriatric Assessment - Hepatobiliary Cancer, Pancreatic Cancer | Phase 2 / Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 526 | 2025-09-01 | 2025-05-31 |
| Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib - Bile Duct Carcinoma, Gall Bladder Cancer | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 60 | 2025-06-01 | 2025-06-17 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer Treatment :Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorili - Gallbladder Cancer Unresectable | Phase 2 | Enrolling by invitation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 44 | 2025-05-01 | 2025-12-30 |
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088 - Advanced Solid Tumors, HER2 Mutation | Phase 2 | Recruiting | Bayer | 111 | 2025-02-13 | 2026-11-04 |
| Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer Capecitabine, Toripalimab - Gallbladder Cancer, Hilar Cholangiocarcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 110 | 2024-11-12 | 2024-12-05 |
| Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1 - Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Zhengzhou University | 50 | 2024-11-08 | 2025-03-30 |
| Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab. - Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2024-09-01 | 2025-02-28 |
| Evaluating Perioperative Outcomes: Dexmedetomidine vs Lignocaine in Laparoscopic Chlolecystectomy inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h, inj. lignocaine infusion @1-2 mg/kg/h - Hemodynamics Instability, Post Operative Pain | Phase 2 / Phase 3 | Recruiting | Sahiwal medical college sahiwal | 140 | 2024-08-06 | 2024-12-18 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
Showing 20 of 143. Sign in to see all of them.
Gallbladder Neoplasms (127) · Cholangiocarcinoma (59) · Bile Duct Neoplasms (44) · Biliary Tract Neoplasms (33) · Carcinoma, Hepatocellular (24) · Liver Neoplasms (17) · Pancreatic Neoplasms (17) · Stomach Neoplasms (14) · Colorectal Neoplasms (11) · Esophageal Neoplasms (10) · Neoplasm Metastasis (9) · Prostatic Neoplasms (9) · Colonic Neoplasms (8) · Neoplasms (8) · Ovarian Neoplasms (8)
Digestive System Diseases (143) · Biliary Tract Diseases (141) · Neoplasms by Site (128) · Digestive System Neoplasms (127) · Neoplasms (120) · Biliary Tract Neoplasms (94) · Neoplasms by Histologic Type (84) · Neoplasms, Glandular and Epithelial (83) · Adenocarcinoma (81) · Carcinoma (77) · Bile Duct Diseases (43) · Liver Diseases (33) · Gastrointestinal Diseases (25) · Endocrine Gland Neoplasms (24)
Gemcitabine (37) · Cisplatin (20) · Capecitabine (19) · Oxaliplatin (19) · Fluorouracil (14) · Leucovorin (10) · 130-nm albumin-bound paclitaxel (7) · durvalumab (7) · pembrolizumab (7) · Bevacizumab (6) · Magnetic Resonance Spectroscopy (6) · Specimen Handling (6) · Erlotinib Hydrochloride (5) · Sorafenib (5) · Trastuzumab (5)
National Cancer Institute (NCI) (20) · Alliance for Clinical Trials in Oncology (4) · Shanghai Jiao Tong University School of Medicine (4) · M.D. Anderson Cancer Center (3) · Tianjin Medical University Cancer Institute and Hospital (3) · ASLAN Pharmaceuticals (2) · Asan Medical Center (2) · Case Comprehensive Cancer Center (2) · EMD Serono Research & Development Institute, Inc. (2) · Eastern Hepatobiliary Surgery Hospital (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · Merck Sharp & Dohme LLC (2)
United States (75) · China (33) · South Korea (11) · Spain (10) · France (9) · Germany (9) · Italy (7) · Japan (7) · United Kingdom (7) · Canada (6) · Australia (5) · Taiwan (5) · India (4) · Sweden (4) · Switzerland (4)
Steven R. Alberts, MD (3) · Tanios Bekaii-Saab (3) · Amit Mahipal (2) · Anthony El-Khoueiry (2) · Benjamin Tan, M.D. (2) · Nilofer S Azad (2) · Pascal Bucher, MD (2) · Adeel Riaz, MD (1) · Afshin Dowlati, MD (1) · Ahmed Kaseb (1) · Alaa M Sewefy, MD (1) · Ali Zarrinpar, MD, PhD (1) · Allyson Ocean (1)
PMID 32461347, PMID 12794246, PMID 15558814, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19399502, PMID 19737952, PMID 20375404, PMID 20662793, PMID 20981545, PMID 21556747, PMID 21910897, PMID 21964736, PMID 23640665, PMID 24512954, PMID 24769639, PMID 24852116, PMID 25241229, PMID 25538178, PMID 25964250, PMID 26179201, PMID 26598942, PMID 27095655, PMID 27234522, PMID 27806234, PMID 28388942, PMID 28818953, PMID 29341833, PMID 29433850, PMID 29882997, PMID 30515783, PMID 30642373, PMID 30646854, PMID 30755690, PMID 30811474, PMID 30998813, PMID 31081949, PMID 31253621, PMID 31254596, PMID 31403867, PMID 31407173, PMID 31501784, PMID 31969335, PMID 32165407, PMID 33198671, PMID 33289918, PMID 33362722, PMID 33882143, PMID 34129409
U10CA032102 (4), N01CM00070 (3), N01CM62201 (3), 2023 (2), N01CM17104 (2), U10CA180888 (2), UM1CA186691 (2), 2017 (1), 2018 (1), 2019 (1), 2025 (1), N01CM62202 (1), N01CM62204 (1), N01CM62207 (1), N01CM62209 (1)